Mepsgen

Seoul, South Korea Founded: 2019 • Age: 7 yrs
Developer of human organ model chips for pharmaceutical development

About Mepsgen

Mepsgen is a company based in Seoul (South Korea) founded in 2019 by Yongtae Kim.. Mepsgen has raised $29.26 million across 4 funding rounds from investors including Korean Development Bank, Yuanda Financial Holdings and KB Investment. Mepsgen offers products and services including MEPS-X, MST-X, and NanoCalibur. Mepsgen operates in a competitive market with competitors including Emulate, CN Bio, AxoSim, Mimetas and Nortis, among others.

  • Headquarter Seoul, South Korea
  • Founders Yongtae Kim
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Mepsgen Co., Ltd.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $29.26 M (USD)

    in 4 rounds

  • Latest Funding Round
    $14.84 M (USD), Series C

    Nov 19, 2024

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Mepsgen

Mepsgen offers a comprehensive portfolio of products and services, including MEPS-X, MST-X, and NanoCalibur. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Automated platform for modeling human tissue barriers in drug testing

Tools for scalable production of lipid nanoparticles

Automated system for nanoparticle manufacturing from lab to GMP scale

Funding Insights of Mepsgen

Mepsgen has successfully raised a total of $29.26M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $14.84 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series C — $14.8M
  • First Round

    (01 Aug 2020)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2024 Amount Series C - Mepsgen Valuation Yuanda Financial Holdings , KB Investment
Jul, 2022 Amount Series B - Mepsgen Valuation

investors

Aug, 2021 Amount Series A - Mepsgen Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Mepsgen

Mepsgen has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Korean Development Bank, Yuanda Financial Holdings and KB Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Venture capital fund investing in early-stage tech startups
Founded Year Domain Location
-
Founded Year Domain Location
Sector-agnostic VC firm investing in geographies such as South Korea
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Mepsgen

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Mepsgen

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Mepsgen Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Mepsgen

Mepsgen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emulate, CN Bio, AxoSim, Mimetas and Nortis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of in vitro models for drug development
domain founded_year HQ Location
Organ-on-a-chip platforms are developed for drug discovery applications.
domain founded_year HQ Location
Nerve-on-a-chip technology is advanced by AxoSim for drug development improvement.
domain founded_year HQ Location
Microfluidics-based organ-on-a-chip models for drug evaluation are developed.
domain founded_year HQ Location
Small human tissue segments are generated in microfluidic chips.
domain founded_year HQ Location
Microfluidic devices are developed for industrial applications and brain-on-a-chip models.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Mepsgen

Frequently Asked Questions about Mepsgen

When was Mepsgen founded?

Mepsgen was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Mepsgen located?

Mepsgen is headquartered in Seoul, South Korea.

Who is the current CEO of Mepsgen?

Yongtae Kim is the current CEO of Mepsgen. They have also founded this company.

Is Mepsgen a funded company?

Mepsgen is a funded company, having raised a total of $29.26M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.47M, raised on Aug 01, 2020.

What does Mepsgen do?

Developer of human organ model chips for pharmaceutical development. The company develops and produces a 3D cell cultures organ-on-a-chip platform such as the MEPS-X series and MG-X series to develop drug candidates which target Alzheimers and brain tumors.

Who are the top competitors of Mepsgen?

Mepsgen's top competitors include Emulate, CN Bio and Cellbox Labs.

What products or services does Mepsgen offer?

Mepsgen offers MEPS-X, MST-X, and NanoCalibur.

Who are Mepsgen's investors?
Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available